601 GENOME WAY, HUNTSVILLE, AL
Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
News, Securities Holder Rights or Indentures, Material Contracts
Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
News, Articles of Incorporation
Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Investor Presentation
Announces Date for 2025 Annual Stockholders Meeting
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Contested Proxy Solicitation Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload